This is what a buyer, doctor, or distributor actually pays — in time, money, and expertise — to verify one peptide supplier without PepiScreen. Then what we do differently, and honestly, when you should still commission your own test.
A physician, importer, or serious buyer has four real options. Here they are side-by-side, without spin.
| PepiScreen | Your own private lab test | Ask the distributor for QC | Wait for regulator listing | |
|---|---|---|---|---|
| Turnaround time | Same day Instant for suppliers in the directory; ~2 weeks for a new-supplier assessment request |
4–8 weeks Order sample → ship to lab → queue → test → report → interpretation |
0–10 days If they respond at all, and if you can trust their own documents |
12–36+ months Peptide regulation is coming but not here yet in most markets |
| Cost per verification | A$22 · single supplier audit (27 evidence checks) A$22/mo · Membership: 3 audits + PSA Member Directory The audit is the product. The PSA Member Directory is a professional trade register accessible to Members — not a public browsing catalogue. |
$190–$600+ MS identity or LC-MS; HPLC purity and residual/endotoxin add-ons push comprehensive tests higher — per batch, per supplier |
Free (of money) Self-testing carries an obvious conflict of interest; documents may be recycled |
Free Also unavailable, in most peptide categories, most jurisdictions |
| Coverage | 750+ suppliers in dataset, 32 publicly rated Cross-referenced against every other supplier we've seen |
1 supplier · 1 batch · 1 point in time Whatever arrived in the mail on that day. Next batch is unknown. |
1 supplier's own paperwork No cross-check against other brands using the same lab or upstream factory |
Curated post-hoc list of licensed products, if any exist for that peptide |
| Lab quality assessment | We grade the labs. Our ISO 17025 registry + meta-labelling identifies labs producing suspiciously clean reports across many customers |
You pick a lab and trust it Most buyers can't distinguish a rigorous testing house from a paper-shuffle. Most private tests use whatever lab the sample-broker recommends. |
Whatever the supplier chose Often the same lab that produces the supplier's own certificates |
Regulator-approved labs only, but usually only for products already in that regulator's system |
| Cross-reference (what a single test can't see) | Dataset-wide. Recycled COAs across “different” brands, shared upstream factories, batch-number recycling, lab-shopping between assessments — all surfaced automatically |
Impossible from a single test A perfect result on your batch doesn't tell you the same COA is being used by three other resellers |
None | Limited to that regulator's approved-product set |
| Ongoing surveillance | Continuous. Quarterly re-review, community complaint intake, regulator warning-letter ingestion (FDA / MHRA / TGA). Ratings can move up or down without you asking |
One-shot Your $600 test is a photo, not a movie. Repeat annually to stay current — same cost every time. |
None Distributors rarely republish QC per batch unless a customer forces it |
Only when the regulator itself notices a problem |
| Expertise required | None. Rubric is designed for a physician or buyer with no chemistry background to read at a glance |
Chromatography interpretation, GMP knowledge, peptide sequence chemistry Most buyers hire a consultant to interpret the report they just paid for |
You have to know what to ask for and what the answer means | Regulator-facing summary language, usually intended for pharmacists |
| Best used for | ~90% of buyer and clinician decisions Choosing a supplier, screening a distributor, spot-checking a batch claim, filtering the market to a shortlist |
Regulated product release testing, litigation, novel peptides with no reference data | Contract negotiation with a specific supplier where you already have them shortlisted | Situations where a controlled prescription is legally required and there's an approved product |
A newer class of site — Peptigrity, ChemVerify, KnowYourPeptide — publishes free trust scores based on user reviews plus HPLC purity from a small set of testing labs. They're useful for one thing: US retail e-commerce peptide shops with a paying community. They're structurally blind to everything else.
“We don't sell peptides — we verify them. Trust Score = 50% community reviews + 50% independent HPLC purity averages. Vendor-submitted COAs are rejected.” That's the whole model. No batch-number tracking. No cross-peptide reuse detection. No template-forgery detection. No PDF-to-image doctoring signals. No upstream-factory relabelling checks. No fraud framework of any kind.
Concretely: we cross-checked our private fraud/suspect list (15 confirmed fraud operators, 8 suspects) against Peptigrity's 533-shop index. Zero matches. The suppliers gaming the peptide market on WhatsApp, direct-from-China messaging apps, and Instagram DMs are simply not visible to a US-retail-review platform. Neither is any Australian supplier — Peptigrity lists 0 AU shops in its 533.
If you buy from a US ecommerce peptide store with a big Reddit footprint, Peptigrity's free score is genuinely useful. If you're a doctor in Sydney evaluating a WhatsApp supplier, or a researcher comparing two Chinese factories, or anyone trying to spot a recycled COA, no community rating system is instrumented to catch it. That's the market we cover.
We're not a lab — we're an analytical data engine that audits every lab's paperwork. A lab-owned rating site benefits from selling more tests to the community pool that funds its reviews. We have no lab revenue to protect. Different structure, different incentives, different coverage.
The obvious question a serious buyer asks: what stops a big commercial lab from launching a rating service and out-spending us? The answer is structural, not tactical.
A commercial lab that sells peptide testing services cannot honestly rate the suppliers whose money keeps its instruments running. Every rating is either a soft touch on a paying customer or a punch at a competitor's customer. That's not independence; it's the same conflict a supplier has when it grades its own COA — dressed up in a different lab coat.
PepiScreen has no lab revenue to protect. We don't sell tests, we don't take supplier commissions, and our reviewers are blinded to which suppliers pay membership at the time the rubric is applied (see the Statement of Assurance). That's a moat any competitor with lab-testing revenue simply cannot replicate — it would require them to walk away from the business paying their bills.
The right competitor for a buyer to worry about is one with our independence and better data. We're compounding the data every week; the independence is structural to how we're funded.
One private verification of one supplier, end-to-end, at the low end of a realistic UK / US market.
Even a perfect $600 test on one batch is answering a smaller question than most buyers realise.
The same certificate arriving with vials from four “different” suppliers is invisible to a private test that only sees one. Our cross-reference catches it every time.
Private testing assumes the lab you paid is rigorous. We rank labs and flag ones producing suspiciously clean reports across many customers.
One test is a snapshot. Our quarterly re-review shows whether evidence quality has moved up, sideways, or down over the last three years.
Many resellers ship from the same handful of Chinese manufacturing facilities. Private testing sees the reseller; we map the factory.
We ingest FDA, MHRA, and TGA warning letters and map them to suppliers and labs in our dataset. A private test can't do that.
Suspicious pricing is a red flag. Our purity-vs-price benchmarks per peptide, updated weekly, put every supplier's number in context.
We don't win by pretending we're everything. There are three cases where a private test is still the right call — and where we'd recommend it ourselves:
For everything else — selecting a supplier, filtering the market, checking a specific batch claim, briefing a physician on which providers meet an evidence bar — our rating cross-referenced against a register of 750+ peers is the faster, cheaper, and empirically wider-context answer.